FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Porter Andy (Last) (First) (Middle)							Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY] Date of Earliest Transaction (Month/Day/Year) 01/27/2022									ionship of Reportin all applicable) Director Officer (give title below) Chief Admini		10% Ov Other (s below)	wner (specify
C/O RELAY THERAPEUTICS, INC. 399 BINNEY ST., 2ND FLOOR														C last	i dali al au 1	laiat/Casua	Filing	· (Chaal: An	alia abla
(Street) CAMBR (City)		DGE MA 02139 (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)					n
(- 9)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					action	action 2A. Deemed Execution Date,		3. 4. Securities A Disposed Of (Code (Instr. 5)		ies Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amour Securitie Beneficia Owned F Reported	s Form ally (D) o ollowing (I) (In		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Pi		Price	Transact (Instr. 3 a	ction(s)			(111311.4)
Common Stock 01/27				7/202	7/2022		A		24,170	170 ⁽¹⁾ A \$		\$0.00	47,317 ⁽²⁾			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	4. Transactio Code (Inst				6. Date Ex Expiration (Month/Da	Date	•	nd 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			3. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Nui of	mber ares					
Stock Option (Right to Buy)	\$20.38	01/27/2022			A		48,340		(3)	(01/26/2032	Common Stock	48	,340	\$0.00	48,340)	D	

Explanation of Responses:

- 2. Includes 35,545 shares underlying RSUs.
- 3. The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.

Remarks:

/s/ Brian Adams, as Attorneyin-Fact ** Signature of Reporting Person

01/31/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.